Cryoport, Inc. (NASDAQ: CYRX) has reported its financial results for the fourth quarter and full year ended December 31, 2025. The company's revenue for the full year 2025 increased to $176.2 million, surpassing the high end of its previous guidance. The life sciences services revenue grew 18% year-over-year, including a 22% rise in biostorage/bioservices revenue. Additionally, the commercial cell and gene therapy revenue increased by 29% year-over-year to $33.4 million in 2025.
The company supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025. Looking ahead, Cryoport has provided a full-year 2026 revenue guidance of $190 million to $194 million, representing 8%-10% growth year-over-year.
In a more detailed breakdown, the revenue for the three months ended December 31, 2025, compared to the same period in 2024, and the years ended December 31, 2025, compared to 2024, is as follows:
-
Life sciences services revenue for the fourth quarter of 2025 was $25.0 million, a 16% increase from the same period in 2024. For the full year, life sciences services revenue was $96.5 million, an 18% increase from 2024.
-
Biologistics solutions revenue increased 17% year-over-year for the full year 2025, while biostorage/bioservices revenue experienced a robust 22% growth.
-
Life sciences products revenue for the fourth quarter of 2025 was $20.4 million, a 2% increase from the same period in 2024. For the full year, life sciences products revenue was $79.7 million, a 7% increase from 2024.
The company's total revenue for the fourth quarter of 2025 was $45.5 million, representing a 10% increase from the same period in 2024. For the full year 2025, the total revenue was $176.2 million, a 12% increase from 2024.
Cryoport's gross margin for the full year 2025 was 47.1%, compared to 44.4% for 2024. The gross margin for life sciences services was 48.8% for the full year 2025, an improvement from 46.9% in 2024. The gross margin for life sciences products was 45.2% for the full year 2025, up from 41.7% in 2024.
Operating costs and expenses were $31.7 million for the fourth quarter of 2025, slightly lower than the $32.2 million reported for the same period in 2024. For the full year 2025, operating costs and expenses decreased to $119.9 million, compared to $191.3 million for 2024.
The company reported a net loss for the fourth quarter of 2025 amounting to $11.6 million. However, for the full year 2025, Cryoport reported a net income of $78.3 million, driven primarily by the divestiture of its cryopdp specialty courier business during the second quarter of 2025.
The market has reacted to these announcements by moving the company's shares -2.13% to a price of $11.03. Check out the company's full 8-K submission here.
